These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 29383028)

  • 1. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.
    Sugano K
    Therap Adv Gastroenterol; 2018; 11():1756283X17745776. PubMed ID: 29383028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan fumarate for the management of acid-related diseases.
    Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E
    Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
    Inatomi N; Matsukawa J; Sakurai Y; Otake K
    Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of vonoprazan in patients with erosive esophagitis.
    Zhang M; Xiao Y; Chen M
    Therap Adv Gastroenterol; 2022; 15():17562848221122623. PubMed ID: 36117573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
    Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis.
    Shirai Y; Kawami N; Iwakiri K; Kuwana M
    J Scleroderma Relat Disord; 2022 Feb; 7(1):57-61. PubMed ID: 35386943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review.
    Domingues G; Chinzon D; Moraes-Filho JPP; Senra JT; Perrotti M; Zaterka S
    Prz Gastroenterol; 2023; 18(1):47-55. PubMed ID: 37007753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
    Otake K; Sakurai Y; Nishida H; Fukui H; Tagawa Y; Yamasaki H; Karashima M; Otsuka K; Inatomi N
    Adv Ther; 2016 Jul; 33(7):1140-57. PubMed ID: 27287852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
    Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
    J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test.
    Masaoka T; Kameyama H; Yamane T; Yamamoto Y; Takeuchi H; Suzuki H; Kitagawa Y; Kanai T
    J Neurogastroenterol Motil; 2018 Oct; 24(4):577-583. PubMed ID: 30347936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations.
    Savarino E; Martinucci I; Furnari M; Romana C; Pellegatta G; Moscatelli A; Bodini G; Marabotto E; Savarino V; de Bortoli N; Blandizzi C
    Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1333-1341. PubMed ID: 27428571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potassium-competitive acid blockers and acid-related disorders.
    Huang KZ; Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2024 Jun; 31(3):107-114. PubMed ID: 38483115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data.
    Marabotto E; Ziola S; Savarino V; Giannini EG; Furnari M; Bodini G; Zingone F; Ghisa M; Barberio B; Zentilin P; Savarino E
    Clin Exp Gastroenterol; 2020; 13():99-104. PubMed ID: 32346304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
    Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ
    Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
    Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
    Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease.
    Shinozaki S; Osawa H; Hayashi Y; Sakamoto H; Kobayashi Y; Lefor AK; Yamamoto H
    Biomed Rep; 2017 Sep; 7(3):231-235. PubMed ID: 28894571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases.
    Oshima T; Miwa H
    J Neurogastroenterol Motil; 2018 Jul; 24(3):334-344. PubMed ID: 29739175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
    Habu Y
    Intern Med; 2019 Sep; 58(17):2427-2433. PubMed ID: 31178490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.
    Iwakiri K; Fujiwara Y; Manabe N; Ihara E; Kuribayashi S; Akiyama J; Kondo T; Yamashita H; Ishimura N; Kitasako Y; Iijima K; Koike T; Omura N; Nomura T; Kawamura O; Ohara S; Ozawa S; Kinoshita Y; Mochida S; Enomoto N; Shimosegawa T; Koike K
    J Gastroenterol; 2022 Apr; 57(4):267-285. PubMed ID: 35226174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.